LPL Financial’s C4 Therapeutics CCCC Stock Holding History

LPL Financial’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$845K	Buy	253,850 +685	+0.3%	+$2.55K	﹤0.01%	4671
2026 Q2	$1.18M	Buy	253,165 +6,365	+3%	+$21.8K	﹤0.01%	4284
2026 Q1	$649K	Buy	246,800 +3,495	+1%	+$8.23K	﹤0.01%	4540
2025 Q4	$465K	Buy	243,305 +42,375	+21%	+$100K	﹤0.01%	4783
2025 Q3	$446K	Buy	200,930 +4,675	+2%	+$11.2K	﹤0.01%	4719
2025 Q2	$281K	Buy	196,255 +2,345	+1%	+$3.41K	﹤0.01%	4821
2025 Q1	$310K	Buy	193,910 +123,585	+176%	+$369K	﹤0.01%	4549
2024 Q4	$253K	Buy	70,325 +8,150	+13%	+$40.5K	﹤0.01%	4663
2024 Q3	$354K	Buy	62,175 +40,075	+181%	+$241K	﹤0.01%	4292
2024 Q2	$102K	Buy	+22,100	New	+$132K	﹤0.01%	4740

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Vienna Insurance Group Warsaw, Poland $466M AUM 97.31% 1-Year Est. Return

LPL Financial's CCCC Position: Q3 2026 in Review

LPL Financial increased its C4 Therapeutics (CCCC) stake by 0.27% in Q3 2026, buying an estimated $2.55K and bringing the position to 253,850 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #4671.

LPL Financial first reported a position in CCCC in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.18M in Q2 2026. 38 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

LPL Financial held 253,850 shares of C4 Therapeutics worth $845K as of Q3 2026.
LPL Financial bought 685 C4 Therapeutics shares in Q3 2026, an estimated $2.55K.
C4 Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #4671 holding.
LPL Financial first reported a position in C4 Therapeutics in Q2 2024 and has held it in 10 quarters since.
LPL Financial's C4 Therapeutics position peaked at $1.18M in Q2 2026.
38 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.